Food and Drug Administration (FDA)
NEWS
Novartis is going full steam ahead with its cancer development efforts, recently posting positive results from two ongoing trials for lymphoma and leukemia.
The following features are highlights from the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, held in-person in Atlanta, GA, and virtually from December 11 to 14.
The best way to battle the dominant Delta strain is booster vaccines. So far, initial data suggests boosters are likely to help battle Omicron as well. For that and more COVID-19 news, read on.
A U.S. Congress subcommittee unanimously approved the ACT for ALS bill in a decision that could soon pour massive funding into the search for treatment for this debilitating and deadly disease.
The FDA has approved emergency use authorization for AstraZeneca’s Evusheld cocktail as prophylaxis against COVID-19 infection in adults and adolescents aged at least 12 years.
Researchers in China are busy developing several treatments, combining vaccines and drugs for COVID-19, and also working on monoclonal antibodies treatment.
The company could lay off as many as 1,000 employees as it continues to deal with the controversial treatment.
At Harbinger, Hahn will oversee the development of the Bio-AI diagnostics platform dubbed HarbingerHx, in hopes of detecting cancer in a patient before it is visible or symptomatic.
Neurocrine Biosciences and Acadia Pharmaceuticals posted positive top-line results from their respective Phase III trials on major neurological diseases.
JOBS
IN THE PRESS